Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in...
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/...
New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif., Feb. 23,...
PROVIDENCE, R.I., Feb. 21, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys) and Hitachi High-Tech America, Inc. (HTA) have revealed the...
MENLO PARK, Calif., Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect...
Introducing the AVIEW lineup specialized in simultaneous diagnosis and analysis of thoracic diseasesParticipating in HIMSS on March 3rd and completing...
Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine...
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options.SANTA ANA, Calif., Feb....
WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®...
WARSAW, Poland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- The White Paper was unveiled on 21 February 2025 at the Medical...
Phoenix Molecular Designs Infographic Introduction to PhoenixMD PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b...
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is...
STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- FOURTH QUARTER (OCTOBER - DECEMBER 2024) Order intake SEK 305.0 M (317.7)Net sales SEK...
Professor Valérie Langlois investigates these harmful pollutants and strives to limit their spectacular growth in our environment QUÉBEC CITY, Feb....
Enspyre is a next generation sequencing (NGS) preparation technology enabling higher sensitivity variant calling from a fraction of the data...
EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage...
Exploring new opportunities within the fast-growing market of microfluidics BORDEAUX, France, Feb. 20, 2025 /PRNewswire/ -- Syensqo, a leading specialty...